J P Bilezikian
Papers
1
Total Citations
3
H-Index
1
About
John P. Bilezikian is a towering figure in metabolic bone disease, whose work has fundamentally shaped our understanding of osteoporosis and calcium disorders. His research spans the pathophysiology of primary hyperparathyroidism, the clinical utility of PTH analogs, and the skeletal effects of vitamin D. Bilezikian led seminal studies establishing parathyroid hormone (PTH) as an anabolic therapy for osteoporosis, demonstrating that intermittent PTH administration improves bone microarchitecture and reduces fracture risk—a paradigm shift from purely antiresorptive approaches. His contributions are reflected in over 800 publications, many cited thousands of times, including foundational work on the diagnosis and management of primary hyperparathyroidism. Among his notable achievements, he chaired the NIH Consensus Development Conference on this condition and has received numerous awards, including the American Society for Bone and Mineral Research’s highest honor. His recent work, such as the 2025 phase 1 study of an oral robotic pill delivering teriparatide, continues to push boundaries, aiming to improve drug bioavailability and patient adherence. For students and researchers, Bilezikian’s career exemplifies how rigorous clinical investigation can translate into life-changing therapies for millions.
Research Focus
Key Achievements
Top Papers
- 1